Dr. Galsky on the “new dawn” in bladder-sparing in bladder cancer

“It could be that the integration of a new treatment modality into the bladder-sparing arena is a tipping point that is needed to really have the community embrace this as a reasonable option for patients with bladder cancer,” says Matthew Galsky, MD.

In a video filmed during the 2021 ASCO Annual Meeting, Matthew Galsky, MD, discusses the emergence of new bladder-sparing approaches in the treatment of bladder cancer. Galsky is Professor of Medicine (Hematology and Medical Oncology) and Acting Chief of the Division of Hematology and Medical Oncology for the Mount Sinai Health System, New York City, New York.